MRKR

$0.00

(

+0.00%

)
Quote details

stock

Marker Therapeutics Inc

NASDAQ | MRKR

0.91

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 5, 2025)

$11.67M

Market Cap

-

P/E Ratio

-1.35

EPS

$5.95

52 Week High

$0.81

52 Week Low

HEALTHCARE

Sector

MRKR Chart

Recent Chart
Price Action

MRKR Technicals

Tags:

MRKR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$6.9M
Total Revenue $6.6M
Cost Of Revenue $13M
Costof Goods And Services Sold $13M
Operating Income -$11M
Selling General And Administrative $4.2M
Research And Development $13M
Operating Expenses $18M
Investment Income Net -
Net Interest Income $437K
Interest Income $437K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$6.2M
Income Before Tax -$11M
Income Tax Expense $50K
Interest And Debt Expense -
Net Income From Continuing Operations -$11M
Comprehensive Income Net Of Tax -
Ebit -$4.5M
Ebitda -$4.5M
Net Income -$11M

Revenue & Profitability

Earnings Performance

MRKR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $22M
Total Current Assets $22M
Cash And Cash Equivalents At Carrying Value $19M
Cash And Short Term Investments $19M
Inventory -
Current Net Receivables $2.3M
Total Non Current Assets $0
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $19T
Other Current Assets $484K
Other Non Current Assets -
Total Liabilities $3.5M
Total Current Liabilities $3.5M
Current Accounts Payable $1.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $2.3M
Other Non Current Liabilities -
Total Shareholder Equity $19M
Treasury Stock -
Retained Earnings -$447M
Common Stock $11K
Common Stock Shares Outstanding $9M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$11M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $15M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$11M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$6.9M
Total Revenue $6.6M
Cost Of Revenue $13M
Costof Goods And Services Sold $13M
Operating Income -$11M
Selling General And Administrative $4.2M
Research And Development $13M
Operating Expenses $18M
Investment Income Net -
Net Interest Income $437K
Interest Income $437K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$6.2M
Income Before Tax -$11M
Income Tax Expense $50K
Interest And Debt Expense -
Net Income From Continuing Operations -$11M
Comprehensive Income Net Of Tax -
Ebit -$4.5M
Ebitda -$4.5M
Net Income -$11M

MRKR News

MRKR Profile

Marker Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Marker Therapeutics Inc. is a clinical-stage immuno-oncology company dedicated to developing groundbreaking T-cell-based immunotherapies and peptide-based vaccines targeting hematologic malignancies and solid tumors. Leveraging innovative technologies to mobilize the body’s immune response against cancer, Marker Therapeutics is strategically positioned in a high-growth sector of oncology. Based in Houston, Texas, the company is focused on delivering transformative treatment solutions that aim to significantly enhance patient outcomes and redefine cancer care standards.

CHR
-45.66%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
LNAI
+45.09%
$1.21
VHAI
0.00%
$0.00
GPUS
+8.87%
$0.38
PFE
+1.37%
$24.63
SNAP
-2.00%
$7.32
RUBI
-49.75%
$0.30
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
SLDP
+51.55%
$8.51
YDKG
-5.55%
$0.05
ETHD
+20.91%
$5.26
F
+2.69%
$13.13
SMX
+38.80%
$2.04
PLTR
-1.48%
$187.90
T
-0.36%
$24.44
SOFI
-4.11%
$29.37
DNN
-2.18%
$2.68
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
PINS
-22.92%
$25.36
ACHR
+0.26%
$9.58
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
ONDS
+0.67%
$6.00
WTO
-0.20%
$0.04
CIFR
+9.77%
$24.71
SMCI
-11.11%
$42.13
TEVA
+20.16%
$24.58
INTC
+3.96%
$38.50
BAC
-2.04%
$52.44
AMZN
-1.84%
$249.32
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
NFE
+13.99%
$1.53
AMCR
+3.04%
$8.11
BTG
+1.12%
$4.04
IREN
-1.65%
$66.63
MARA
+3.06%
$17.13
RXRX
-8.08%
$5.00
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
U
+18.12%
$42.37
RGTI
+5.99%
$37.29
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
FUBO
+11.00%
$4.08
RIG
+0.38%
$3.91
ADD
-25.47%
$0.05
WBD
+0.53%
$22.71
BURU
-2.17%
$0.28
NVO
+0.43%
$48.46
QS
+9.93%
$16.97
GRAB
-2.76%
$5.62
WULF
+2.46%
$15.38
CAN
+14.43%
$1.27
BTBT
+3.14%
$3.28
EPWK
-7.75%
$0.06
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
RIOT
-1.58%
$18.97
ZDAI
+13.94%
$0.52
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
APPS
+23.14%
$7.29
HTZ
-0.81%
$6.67
ALIT
-7.22%
$2.50
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
GOOGL
+2.43%
$284.31
NIO
+2.30%
$7.32
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
CGC
-5.83%
$1.12
HPE
+0.59%
$23.70
PCG
+1.05%
$16.32
AG
-7.82%
$10.65
GGB
+5.11%
$3.59
ETWO
0.00%
$3.30
HBAN
+0.13%
$15.29
HOOD
-6.98%
$136.80
RDHL
+0.88%
$1.08
ITUB
+1.55%
$7.49
CMG
+0.96%
$32.04
QBTS
+4.90%
$31.19
MSPR
-27.89%
$0.47
AAPL
-0.18%
$269.53
IONZ
-7.18%
$4.14
SOUN
+2.36%
$15.48
TREX
-31.07%
$32.42
PLTD
+1.97%
$6.47
CHR
-45.66%
$0.07
NVVE
-5.52%
$0.19
MTC
+409.86%
$1.55
ASST
+18.80%
$1.48
RIVN
+23.36%
$15.42
NVDA
-1.75%
$195.21
BYND
-4.31%
$1.33
LNAI
+45.09%
$1.21
VHAI
0.00%
$0.00
GPUS
+8.87%
$0.38
PFE
+1.37%
$24.63
SNAP
-2.00%
$7.32
RUBI
-49.75%
$0.30
PLUG
+4.76%
$2.64
TSLA
+4.00%
$462.07
SLDP
+51.55%
$8.51
YDKG
-5.55%
$0.05
ETHD
+20.91%
$5.26
F
+2.69%
$13.13
SMX
+38.80%
$2.04
PLTR
-1.48%
$187.90
T
-0.36%
$24.44
SOFI
-4.11%
$29.37
DNN
-2.18%
$2.68
AXDX
-61.36%
$0.03
AMD
+2.51%
$256.33
PINS
-22.92%
$25.36
ACHR
+0.26%
$9.58
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
ONDS
+0.67%
$6.00
WTO
-0.20%
$0.04
CIFR
+9.77%
$24.71
SMCI
-11.11%
$42.13
TEVA
+20.16%
$24.58
INTC
+3.96%
$38.50
BAC
-2.04%
$52.44
AMZN
-1.84%
$249.32
KVUE
+1.94%
$16.28
ADAP
-15.14%
$0.05
NFE
+13.99%
$1.53
AMCR
+3.04%
$8.11
BTG
+1.12%
$4.04
IREN
-1.65%
$66.63
MARA
+3.06%
$17.13
RXRX
-8.08%
$5.00
VALE
+3.09%
$12.31
DVLT
-7.83%
$1.64
U
+18.12%
$42.37
RGTI
+5.99%
$37.29
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
FUBO
+11.00%
$4.08
RIG
+0.38%
$3.91
ADD
-25.47%
$0.05
WBD
+0.53%
$22.71
BURU
-2.17%
$0.28
NVO
+0.43%
$48.46
QS
+9.93%
$16.97
GRAB
-2.76%
$5.62
WULF
+2.46%
$15.38
CAN
+14.43%
$1.27
BTBT
+3.14%
$3.28
EPWK
-7.75%
$0.06
SRM
+53.27%
$10.30
TLRY
+3.62%
$1.28
BMNR
+4.89%
$41.39
NCLH
-0.95%
$18.61
RIOT
-1.58%
$18.97
ZDAI
+13.94%
$0.52
HIMS
+3.11%
$44.12
NOK
+0.51%
$6.84
APPS
+23.14%
$7.29
HTZ
-0.81%
$6.67
ALIT
-7.22%
$2.50
KDLY
-11.88%
$0.78
NGD
+2.48%
$6.80
GOOGL
+2.43%
$284.31
NIO
+2.30%
$7.32
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
CGC
-5.83%
$1.12
HPE
+0.59%
$23.70
PCG
+1.05%
$16.32
AG
-7.82%
$10.65
GGB
+5.11%
$3.59
ETWO
0.00%
$3.30
HBAN
+0.13%
$15.29
HOOD
-6.98%
$136.80
RDHL
+0.88%
$1.08
ITUB
+1.55%
$7.49
CMG
+0.96%
$32.04
QBTS
+4.90%
$31.19
MSPR
-27.89%
$0.47
AAPL
-0.18%
$269.53
IONZ
-7.18%
$4.14
SOUN
+2.36%
$15.48
TREX
-31.07%
$32.42
PLTD
+1.97%
$6.47

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.